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Peptides in medicine
Peptides have long been heralded as promising molecules for the treatment and management of a variety of disease states including cancer, diabetes and inflammatory disease [1] . They represent the interface between naturally occurring biologics and chemically synthesised active pharmaceutical ingredients, offering high selectivity for molecular targets, leading to increased therapeutic efficacy and lower capacity for side effects. Their widespread implementation throughout medicine has been limited by their relatively expensive cost of manufacture and poor bioavailability. Despite these challenges researchers, clinicians and the pharmaceutical industry continue to work together in an attempt to clinically translate peptides of therapeutic value. Issues relating to ease and cost of synthesis can be remedied by creating ultrashort peptide pharmacophores, composed of seven or less amino acids, which retain pharmacological properties of larger peptides and proteins. Short peptides are more attractive to the pharmaceutical industry as it is cheaper to scale-up their manufacture and they are more likely to be clinically translated for the benefit of patients. The area of peptidomimetics, including beta-peptides [2] , D-enantiomeric variants [3] and peptoids [4] , has resulted in a wealth of unnatural peptide-like structures which demonstrate improved stability profiles. Their success is exemplified by orally active angiotensin-converting-enzyme inhibitors (ACE inhibitors), for example captopril, widely prescribed for the treatment of hypertension and congestive heart failure since the early 1980s [5] .
Peptides as antimicrobials
Peptides potential as antimicrobial therapies stem from their role as mediators of the innate immune response, serving as important weapons in nature and increasingly medicine for combating infection and controlling the host response to pathogens [6] . Their promise lies in not only in their ability to provide direct antimicrobial action via a variety of extracellular and intracellular targets but they also have the potential to harness the body's own defences, utilising the ubiquitous properties peptides possess throughout nature, to prevent infection. This is demonstrated by the use of peptides as immune adjuvants in vaccine development, replacing components with questionable safety such as aluminium [7] . Traditional antimicrobials are susceptible to resistance development due to targeting of specific microbial receptors or biomolecular mechanisms [8] . There is an urgent need to develop the next generation of antimicrobial therapies, which act using several mechanisms, to limit induction of drug resistance and address the challenge of multidrug resistance. Serious concerns exist regarding increased antimicrobial resistance and the relative lack of new antimicrobials in development [9] . Peptides are not completely devoid of resistance development with recent reports of colistin's reduced efficacy in China [10] [12] . Researchers continue to explore a variety of new peptide templates for improved antimicrobial efficacy, reduced toxicity, and greater microbial specificity, harnessing the power of molecular modelling and structure activity relationships to guide the design of unique amino acid sequences [13] . An increasingly exciting field of research involves the development of peptide-based nanomaterials which can be designed from the "bottom-up" to display optimal functional and pharmacological characteristics for their intended use
Peptides as nanomaterial therapeutics
Just as peptides can be tailored to demonstrate antimicrobial characteristics, their structure can be modified to enable them to assemble spontaneously into highly defined nanostructures. These self-assembling peptides are composed of amino acid building blocks which organise, via intermolecular interactions, into nanomaterial structures in response to physiological stimuli including: pH, temperature, ionic strength, and the presence of specific enzymes [14] . By modifying the amino acid sequence we can control whether these peptides assemble into hydrogels composed of nanofibers or peptide nanotube structures. Their responsiveness to changing physiological stimuli makes them promising platforms throughout the drug delivery and biomaterial fields. The properties that dictate a peptide's ability to self-assemble are very similar to the principles that govern the activity of antimicrobial peptides, most significant of which is the hydrophobic:hydrophilic/charge balance of the peptide primary sequence [14] . Therefore researchers are able to control not only the process of self-assembly in response to stimuli but also pharmacological properties such as antimicrobial activity. In this way biofunctional nanomaterials can be designed and developed for specific functional requirements. These platforms have huge potential within infection treatment and prevention. Peptides are ideal materials for medical applications as they can be designed to demonstrate inherent biocompatibility, antimicrobial activity, biodegradability and possess numerous chemical groups which can be utilized to tailor functional properties (e.g. mechanical strength, stability, hydrogel formation). They have many advantages over current synthetic materials used in healthcare. Peptides possess vast chemical versatility due to the varying nature of their amino acid R-group. This is proven by how they are harnessed throughout nature. They can be utilised to create materials with very specific functionalities and with the potential to attach a variety of molecules including drugs [15] . As amino acids represent the building blocks of peptide, proteins and tissues they exist throughout the body possessing enhanced biocompatibility compared to synthetic based polymeric and nanomaterial systems. The amino acid sequence can also be altered to tailor biodegradation to specific requirements and release conjugated drug molecules for improved efficacy. Biologically derived peptides are proteins, from animals and plants, have been studied extensively for use as medical materials (e.g. collagen, silk) [16, 17] . However their use is limited as they require expensive post modification to both purify and tailor mechanical and biological properties to their clinical purpose.
Future peptide nanomaterial technologies
Self-assembling peptide materials demonstrate significant potential for clinical translation as evidenced by the examples of octreotide which has been recently granted regulatory approval as a therapy for acromegaly [1] . Both peptide hydrogel and nanotube platforms have a variety of potential clinical applications in the antimicrobial field. Their most obvious use is as a hydrogel wound therapy given peptides form the building blocks of tissues and skin. Peptides can be manufactured within the laboratory to reproduce the unique mechanical and biological properties of natural tissue, with the potential to provide both antimicrobial and anti-inflammatory action [15] . Peptide hydrogels can represent the next generation of medical device coatings, triggered to respond to infection development via pathogenic stimuli (e.g. specific bacterial enzymes) thereby providing prolonged protection from bacterial attachment and biofilm formation [18, 19] . An easy to synthesise low molecular weight peptide has the potential to widely be exploited as immune adjuvants for vaccines, 3D cell culture, cell and bioactive molecule (e.g. genes) delivery, bioimaging agents and diagnostics. Peptide nanotube platforms have huge potential as drug delivery platforms for transversing biological barriers, for example the outer membrane of Gramnegative bacteria, mimicking the value of their carbon counterparts in terms of therapeutic applications but with improved chemical functionality for drug conjugation and reduced toxicity concerns [20] . Their value may lie in encapsulating and extending the spectrum of 
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